Furthermore, when using RIPK3 as a therapeutic target for NASH, the patient population must be carefully selected, as its inhibition may exacerbate insulin resistance and intolerance in obese individuals [141]. Here, RIPK3 is linked to metabolic dysfunction-associated steatohepatitis.